Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of Darolutamide, Enzalutamide and Apalutamide for Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) - EXTension of the DEAR Real-world Study (NCT05362149)

NCT06013475 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT06013475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06013475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of Darolutamide, Enzalutamide and Apalutamide for Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) - EXTension of the DEAR Real-world Study (NCT05362149)
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
August 31, 2023
Completion date
October 28, 2024
Enrollment
1,375 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-metastatic castration-resistant prostate cancer